# NIST Micronutrients Measurement Quality Assurance Program Summer 2009 Comparability Studies 

Results for Round Robin LXVI Fat-Soluble Vitamins and Carotenoids in Human Serum and Round Robin 31 Ascorbic Acid in Human Serum

David L. Duewer
Jeanice B. Thomas

National Institute of Standards and Technology

# NIST Micronutrients Measurement Quality Assurance Program Summer 2009 Comparability Studies 

Results for Round Robin LXVI Fat-Soluble Vitamins and Carotenoids in Human Serum and Round Robin 31 Ascorbic Acid in Human Serum

David L. Duewer
Jeanice B. Thomas
Chemical Sciences Division
Materials Measurement Laboratory

April, 2013

U.S. Department of Commerce

Rebecca Blank, Acting Secretary
National Institute of Standards and Technology
Patrick D. Gallagher, Under Secretary of Commerce for Standards and Technology and Director
(This page intentionally blank)


#### Abstract

The National Institute of Standards and Technology coordinates the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. This report describes the design of and results for the Summer 2009 MMQAP measurement comparability improvement studies: 1) Round Robin LXVI Fat-Soluble Vitamins and Carotenoids in Human Serum and 2) Round Robin 31 Total Ascorbic Acid in Human Serum. The materials for both studies were shipped to participants in June 2009; participants were requested to provide their measurement results by September 28, 2009.


## Keywords

Human Serum<br>Retinol, $\alpha$-Tocopherol, $\gamma$-Tocopherol, Total and Trans- $\beta$-Carotene Total Ascorbic Acid

## Table of Contents

Abstract ..... iii
Keywords ..... iii
Table of Contents ..... iv
Introduction ..... 1
Round Robin LXVI: Fat-Soluble Vitamins and Carotenoids in Human Serum ..... 1
Round Robin 31: Vitamin C in Human Serum ..... 2
References ..... 3
Appendix A. Shipping Package Inserts for RR66 ..... A1
Appendix B. Final Report for RR66 ..... B1
Appendix C. "All-Lab Report" for RR66 ..... C1
Appendix D. Representative "Individualized Report" for RR66 ..... D1
Appendix E. Shipping Package Inserts for RR31 ..... E1
Appendix F. Final Report for RR31 ..... F1
Appendix G. "All-Lab Report" for RR31 ..... G1
Appendix H. Representative "Individualized Report" for RR31 ..... H1

## Introduction

Beginning in 1988, the National Institute of Standards and Technology (NIST) has coordinated the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. The MMQAP provides participants with measurement comparability assessment through use of interlaboratory studies, Standard Reference Materials (SRMs) and control materials, and methods development and validation. Serum-based samples with assigned values for the target analytes (retinol, alphatocopherol, gamma/beta-tocopherol, trans- and total beta-carotene, and total ascorbic acid) and performance-evaluation standards are distributed by NIST to laboratories for analysis.

Participants use the methodology of their choice to determine analyte content in the control and study materials. Participants provide their data to NIST, where it is compiled and evaluated for trueness relative to the NIST value, within-laboratory precision, and concordance within the participant community. NIST provides the participants with a technical summary report concerning their performance for each exercise and suggestions for methods development and refinement. Participants who have concerns regarding their laboratory's performance are encouraged to consult with the MMQAP coordinators.

All MMQAP interlaboratory studies consist of individual units of batch-prepared samples that are distributed to each participant. For historical reasons these studies are referred to as "Round Robins". The MMQAP program and the nature of its studies are described elsewhere. [1,2]

## Round Robin LXVI: Fat-Soluble Vitamins and Carotenoids in Human Serum

Participants in the MMQAP Fat-Soluble Vitamins and Carotenoids in Human Serum Round Robin LXVI comparability study (hereafter referred to as RR66) received five liquid-frozen human serum test samples for analysis. Unless multiple vials were previously requested, participants received one vial of each serum. These sera were shipped on dry ice to participants in June 2009. The communication materials included in the sample shipment are provided in Appendix A.

Participants are requested to report values for all fat-soluble vitamin-related analytes that are of interest to their organizations. Not all participants report values for the target analytes, and many participants report values for non-target analytes.

The final report delivered to every participant in RR66 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of the overall results that may be of broad interest. This cover letter is reproduced as Appendix B.
- The "All-Lab Report" that lists all of the reported measurement results, a number of consensus statistics for analytes reported by more than one participant, and the mean median and pooled SD from any prior distributions of the serum. This report also provides a numerical "score card" for each participant's measurement comparability for the more commonly reported analytes. This report is reproduced as Appendix C.
- An "Individualized Report" that graphically analyzes each participant’s results for all analytes reported by at least five participants. This report also provides a graphical summary of their measurement comparability. The graphical tools used in this report are described in detail elsewhere [3]. An example "Individualized Report" is reproduced as Appendix D.


## Round Robin 31: Vitamin C in Human Serum

Participants in the MMQAP Vitamin C in Human Serum Round Robin 31 comparability study (hereafter referred to as RR31) received four frozen serum test samples, one frozen control serum, and a solid ascorbic acid control material for analysis. Unless multiple vials were previously requested, participants received one vial of each material. These sample materials were shipped on dry ice to participants in June 2009. The communication materials included in the sample shipment are provided in Appendix E.

The test and control serum materials were prepared by adding equal volumes of $10 \%$ metaphosphoric acid (MPA) to human serum that had been spiked with ascorbic acid. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, the participants report only total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid). Participants are also encouraged to prepare calibration solutions from the supplied solid control to enable calibrating their serum measurements to the same reference standard.

The final report delivered to every participant in RR31 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of overall results that may be of broad interest. This cover letter is reproduced as Appendix F.
- The "All-Lab Report" that summarizes all of the reported measurement results and provides several consensus statistics. This report is reproduced as Appendix G.
- An "Individualized Report" that graphically analyzes each participant's results for TAA, including a graphical summary of their measurement comparability. The graphical tools used in this report are described in detail elsewhere [3]. An example "Individualized Report" is reproduced as Appendix H .


## References

1 Duewer DL, Brown Thomas J, Kline MC, MacCrehan WA, Schaffer R, Sharpless KE, May WE, Crowell JA. NIST/NCI Micronutrients Measurement Quality Assurance Program: Measurement Repeatabilities and Reproducibilities for Fat-Soluble Vitamin-Related Compounds in Human Sera. Anal Chem 1997;69(7):1406-1413.

2 Margolis SA, Duewer DL. Measurement Of Ascorbic Acid in Human Plasma and Serum: Stability, Intralaboratory Repeatability, and Interlaboratory Reproducibility. Clin Chem 1996;42(8):1257-1262.

3 Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT, Sowell AL. Micronutrients Measurement Quality Assurance Program: Helping Participants Use Interlaboratory Comparison Exercise Results to Improve Their Long-Term Measurement Performance. Anal Chem 1999;71(9):1870-1878.

## Appendix A. Shipping Package Inserts for RR66

The following three items were included in each package shipped to an RR66 participant:

- Cover letter
- Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter and datasheet were enclosed in a sealed waterproof bag along with the samples themselves. The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.

UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-

June 1, 2009
Dear Colleague:
Enclosed are samples for the second fat-soluble vitamins and carotenoids in serum study (Round Robin LXVI) for the 2009 NIST Micronutrients Measurement Quality Assurance Program. The set of samples (Sera 357-361) consists of one vial of each of five liquid-frozen serum samples for analysis along with a form for reporting your results. These samples should be stored in the dark at or below $-20^{\circ} \mathrm{C}$ upon receipt. When reporting your results, please submit one value for each analyte for a given serum sample. If a value obtained is below your limit of quantification, please indicate this result on the form by using NQ (Not Quantified). Results are due to NIST by September 28, 2009. Results received more than two weeks after the due date may not be included in the summary report for this round robin study. The feedback report concerning the study will be distributed in October 2009.

Samples should be allowed to stand at room temperature under subdued light until thawed. We recommend that sample mixing be facilitated with 3 to 5 min agitation in an ultrasonic bath or at least 15 $\min$ at room temperature with intermittent swirling. (CAUTION: Vigorous shaking will cause foaming and possibly interfere with accurate measurement. The rubber stopper contains phthalate esters that may leach into the sample upon intermittent contact of the liquid sample with the stopper. These esters absorb strongly in the UV region and elute near retinol in most LC systems creating analytical problems.) Water should not be added to the liquid-frozen samples.

For consistency, we request that laboratories use the following absorptivities ( $\mathrm{dL} / \mathrm{g} \cdot \mathrm{cm}$ ): retinol, 1843 at 325 nm (ethanol); retinyl palmitate, 975 at 325 nm (ethanol); $\alpha$-tocopherol, 75.8 at 292 nm (ethanol); $\gamma$ tocopherol, 91.4 at 298 nm (ethanol); $\alpha$-carotene, 2800 at 444 nm (hexane); $\beta$-carotene, 2560 at 450 nm (ethanol), 2592 at 452 nm (hexane); and lycopene, 3450 at 472 nm (hexane).

Please report your results for Round Robin LXVI by e-mail to david.duewer@nist.gov or fax to 301-9770685. If you have questions or comments regarding this study, please call me at (301) 975-3120 or e-mail me at jbthomas@nist.gov.



Research Chemist
Analytical Chemistry Division
Chofnical Science and Technology Laboratory

## Enclosures

$\qquad$
$\qquad$
Round Robin LXVI: Human Sera
NIST Micronutrients Measurement Quality Assurance Program

| Analyte | 357 | 358 | 359 | 360 | 361 | Units* |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| total retinol |  |  |  |  |  |  |
| trans-retinol |  |  |  |  |  |  |
| didehydroretinol |  |  |  |  |  |  |
| retinyl palmitate |  |  |  |  |  |  |
| $\alpha$-tocopherol |  |  |  |  |  |  |
| $\gamma / \beta$-tocopherol |  |  |  |  |  |  |
| $\delta$-tocopherol |  |  |  |  |  |  |
| total $\beta$-carotene |  |  |  |  |  |  |
| trans- $\beta$-carotene |  |  |  |  |  |  |
| total cis- $\beta$-carotene |  |  |  |  |  |  |
| total $\alpha$-carotene |  |  |  |  |  |  |
| total lycopene |  |  |  |  |  |  |
| trans-lycopene |  |  |  |  |  |  |
| total $\beta$-cryptoxanthin |  |  |  |  |  |  |
| total $\alpha$-cryptoxanthin |  |  |  |  |  |  |
| total lutein |  |  |  |  |  |  |
| total zeaxanthin |  |  |  |  |  |  |
| total lutein\&zeaxanthin |  |  |  |  |  |  |
| total coenzyme Q10 |  |  |  |  |  |  |
| ubiquinol $\left(\mathrm{QH}_{2}\right)$ |  |  |  |  |  |  |
| ubiquinone (Qox) |  |  |  |  |  |  |
| phylloquinone $\left(\mathrm{K}_{1}\right)$ |  |  |  |  |  |  |
| 25-hydroxyvitamin D |  |  |  |  |  |  |

Other measurands?

|  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  |  |  |  |  |  |

Were the liquid-frozen samples (357 to 361) frozen when received? Yes | No Comments:
$\qquad$
$\qquad$

## Fat-Soluble Vitamins Round Robin LXVI NIST Micronutrients Measurement Quality Assurance Program

## Packing List and Shipment Receipt Confirmation Form

This box contains: one vial each of the following five FSV M ${ }^{2}$ QAP sera

| Serum | Form | Reconstitute? | Vial/Cap |
| :---: | :---: | :---: | :---: |
| \#357 | Liquid frozen | No | 2 mL amber, red cap |
| \#358 | Liquid frozen | No | 2 mL amber, blue cap |
| \#359 | Liquid frozen | No | 2 mL amber, green cap |
| \#360 | Liquid frozen | No | 2 mL amber, green cap |
| \#361 | Liquid frozen | No | 10 mL amber, silver cap |

Please 1) Open the pack immediately
2) Check that it contains all of the above samples
3) Check if the vials are intact
4) Store the sera at $-20^{\circ} \mathrm{C}$ or below until analysis
5) Complete the following information
6) Fax the completed form to us at 301-977-0685
(or email requested information to david.duewer@nist.gov)

1) Date this shipment arrived:
2) Are all five sera vials intact? Yes | No If "No", which one(s) were damaged?
3) Was there any dry-ice left in cooler? Yes | No
4) Did the liquid frozen samples arrive frozen? Yes | No
5) At what temperature are you storing the serum samples? $\qquad$ ${ }^{\circ} \mathrm{C}$
6) When do you anticipate analyzing these samples? $\qquad$

## Your prompt return of this information is appreciated.

The M ${ }^{2}$ QAP Gang

## Appendix B. Final Report for RR66

The following two pages are the final report as provided to all participants:

- Cover letter.
- An information sheet that:
o describes the contents of the "All-Lab" report,
o describes the content of the "Individualized" report,
o describes the nature of the test samples and details their previous distributions, if any, and
o summarizes aspects of the study that we believe may be of interest to the participants.


## Dear Colleague:

Enclosed is the summary report of the results for round robin LXVI (RR66) of the 2009 NIST Micronutrients Measurement Quality Assurance Program ( $\mathrm{M}^{2} \mathrm{QAP}$ ) for the fat-soluble vitamins and carotenoids in human serum. Included in this report are: 1) a summary of data and measurement comparability scores for all laboratories, 2) a detailed graphical analysis of your results; and 3) a graphical summary of your measurement comparability.

Your overall measurement comparability is summarized in the "Score Card" summary, page 6 of the All Lab Report. Combined results rated 1 to 3 are within 1 to 3 standard deviations of the assigned value, respectively; those rated 4 are $>3$ standard deviations from the assigned value. Similar information is presented graphically in the "target plots" that are the last page of your Individualized Report. If you have concerns regarding your laboratory's performance, please contact us for consultation.

We are in the process of finalizing the value-assignment for SRM 968e, Fat-Soluble Vitamins, Carotenoids, and Cholesterol in Human Serum. This SRM will consist of three different levels for the core analytes (retinol, $\alpha$-tocopherol, and $\beta$-carotene). We will notify you when the SRM becomes available for purchase (estimated Spring 2010).

Samples for the first 2010 QA interlaboratory exercise will be shipped during the week of December 7, 2009. If you have any questions regarding this report, please contact Dave Duewer at david.duewer@nist.gov or me at jbthomas@nist.gov, tel: 301/975-3120, or fax: 301/977-0685.


Research Chemist
Analytical Chemistry Division Chemical Science and Technology Laboratory


David L. Duewer, Ph.D
Research Chemometrician Analytical Chemistry Division
Chemical Science and Technology Laboratory

Cc: L.C. Sander

The NIST M ${ }^{2}$ QAP Round Robin LXVI (RR66) report consists of:

| Page | "All Lab" Report |
| :---: | :--- |
| $1-4$ | A listing of all results and statistics for all analytes. |
| 5 | A legend for the list of results and statistics. |
| 6 | The text Comparability Summary ("Score Card") of measurement performance. |
| Page | "Individualized" Report |
| 1 | Your values, the number of labs reporting values, and our assigned values. |
| 2 to | "Four Plot" summaries of your current and past measurement performance, one page for |
| n | each analyte you report that is also reported by at least 8 other participants. |
| $\mathrm{n}+1$ | The graphical Comparability Summary (target plot) of measurement performance. |

Samples. Five samples were distributed in RR66.

| Serum | Description | Prior Distributions |
| :---: | :--- | :--- | :--- | :--- |
| 337 | Fresh-frozen, native, multi-donor, prepared in 2009. <br> This is Level I of candidate SRM 968e. |  |
| 358 | Fresh-frozen, native, multi-donor, prepared in 2009. <br> This is Level II of candidate SRM 968e. |  |
| 359 | Fresh-frozen, native, multi-donor, prepared in 2009. <br> This is Level III of candidate SRM 968e. |  |
| 360 | Fresh-frozen, native, multi-donor, prepared in 2008 | \#356:RR65-3/09 |

## Results

1) Sera Stability. There was no significant change in the median level or measurement variability of any measurand in either of the two previously distributed materials. However, measurement variability for some analytes appears to have increased in the SRM 968d material. We will closely monitor the stability of this material; we hope to replace it with in the very near future.
2) Candidate SRM 968e. Sera \#357 to \#359 are the components of candidate SRM 968e. All three of these materials were prepared by blending commercially available materials without spiking. The materials were designed to represent relatively low, middling, and relatively high levels of retinol, $\alpha$ Tocopherol and $\beta$-carotene. We anticipate this material being available for purchase early-2010.
3) Environmental Stability. The initial set of samples for Lab 110 arrived thawed. After a replacement set was successfully delivered, both sets (listed as 110 and 110.1) were analyzed under reproducibility conditions. The is appreciable difference in the reported values for any analyte in any of the materials.

## Appendix C. "All-Lab Report" for RR66

The following six pages are the "All-Lab Report" as provided to all participants, with two exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.

The data summary in the "All-Lab Report" has been altered to ensure confidentiality of identification codes assigned to laboratories. The only attributed results are those reported by NIST. The NIST results are not used in the assessment of the consensus summary results of the study.
Round Robin LXVI Laboratory Results

|  | Total Retinol, $\mu \mathrm{g} / \mathrm{mL}$ |  |  |  |  | trans-Retinol, $\mu \mathrm{g} / \mathrm{mL}$ |  |  |  |  | Retinyl Palmitate, $\mu \mathrm{g} / \mathrm{mL}$ |  |  |  |  | $\alpha$-Tocopherol, $\mu \mathrm{g} / \mathrm{mL}$ |  |  |  |  | $\gamma / \beta$-Tocopherol, $\mu \mathrm{g} / \mathrm{mL}$ |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Lab | 357 | 358 | 359 | 360 | 361 | 357 | 358 | 359 | 360 | 361 | 357 | 358 | 359 | 360 | 361 | 357 | 358 | 359 | 360 | 361 | 357 | 358 | 359 | 360 | 361 |
| 110.2??? | 0.328 | 0.433 | 0.522 | 0.608 | 0.275 |  |  |  |  |  | 0.002 | 0.020 | 0.089 | 0.042 | 0.002 | 7.09 | 10.03 | 17.00 | 9.68 | 4.91 | 1.18 | 0.98 | 1.58 | 1.59 | 0.83 |
| 110.3??? | 0.293 | 0.463 | 0.522 | 0.623 | 0.281 |  |  |  |  |  | 0.006 | 0.021 | 0.093 | 0.043 | 0.000 | 6.28 | 10.66 | 17.54 | 10.00 | 5.07 | 1.13 | 1.05 | 1.53 | 1.66 | 0.82 |
| 119.1??? | $\geq 0.274$ | $\geq 0.380$ | $\geq 0.480$ | $\geq 0.571$ | $\geq 0.289$ | 0.274 | 0.380 | 0.480 | 0.571 | 0.289 |  |  |  |  |  | 6.80 | 10.51 | 18.74 | 11.11 | 6.14 | 1.83 | 1.48 | 0.24 | 2.39 | 1.43 |
| FSV-BA | 0.366 | 0.523 | 0.675 | 0.770 | 0.357 |  |  |  |  |  | 0.019 | 0.063 | 0.155 | 0.044 | 0.029 | 6.62 | 9.99 | 18.18 | 10.16 | 5.88 | 2.04 | 1.58 | 2.54 | 2.69 | 1.67 |
| FSV-BB | 0.357 | 0.522 | 0.655 | 0.733 | 0.361 |  |  |  |  |  | 0.007 | 0.021 | 0.070 | 0.036 | 0.007 | 6.49 | 9.94 | 17.88 | 10.14 | 5.81 | 1.82 | 1.43 | 2.27 | 2.41 | 1.47 |
| FSV-BC | 0.373 | 0.530 | 0.670 | 0.772 | 0.356 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| FSV-BD | 0.387 | 0.531 | 0.732 | 0.851 | 0.375 |  |  |  |  |  |  |  |  |  |  | 7.10 | 10.70 | 20.50 | 11.90 | 6.50 |  |  |  |  |  |
| FSV-BE | 0.343 | 0.504 | 0.675 | 0.713 | 0.287 |  |  |  |  |  |  |  |  |  |  | 5.66 | 9.22 | 18.15 | 9.34 | 2.41 | 1.77 | 1.44 | 2.49 | 2.41 | 1.30 |
| FSV-BF | 0.390 | 0.560 | 0.710 | 0.840 | 0.370 |  |  |  |  |  |  |  |  |  |  | 7.10 | 10.50 | 18.80 | 10.90 | 5.00 |  |  |  |  |  |
| FSV-BG | 0.350 | 0.497 | 0.645 | 0.748 | 0.336 |  |  |  |  |  | 0.016 | 0.049 | 0.219 | 0.045 | 0.024 | 6.43 | 9.95 | 18.40 | 10.41 | 5.86 | 1.84 | 1.44 | 2.34 | 2.50 | 1.46 |
| FSV-BH | 0.347 | 0.511 | 0.619 | 0.720 | 0.315 |  |  |  |  |  |  |  |  |  |  | 6.98 | 10.64 | 18.71 | 10.45 | 5.67 | 2.29 | 1.75 | 2.70 | 2.91 | 1.66 |
| FSV-BJ | 0.331 | 0.473 | 0.626 | 0.718 | 0.321 |  |  |  |  |  | $n q$ | $n q$ | 0.092 | $n q$ | $n q$ | 6.08 | 9.99 | 18.34 | 10.24 | 5.50 | 1.79 | 1.43 | 2.28 | 2.48 | 1.50 |
| FSV-BK | 0.364 | 0.494 | 0.659 | 0.722 | 0.450 |  |  |  |  |  |  |  |  |  |  | 6.86 | 10.46 | 19.26 | 10.83 | 6.37 |  |  |  |  |  |
| FSV-BL | 0.320 | 0.430 | 0.540 | 0.600 | 0.290 |  |  |  |  |  |  |  |  |  |  | 7.32 | 11.20 | 19.38 | 11.20 | 6.46 |  |  |  |  |  |
| FSV-BM | 0.370 | 0.480 | 0.690 | 0.730 | 0.370 |  |  |  |  |  |  |  |  |  |  | 7.10 | 10.20 | 19.70 | 10.90 | 6.20 |  |  |  |  |  |
| FSV-BN | 0.316 | 0.428 | 0.550 | 0.638 | 0.291 |  |  |  |  |  | 0.003 | 0.014 | 0.074 | 0.032 | 0.003 | 6.10 | 8.80 | 15.53 | 9.27 | 4.51 | 1.37 | 1.01 | 1.62 | 1.83 | 1.08 |
| FSV-BNa | 0.309 | 0.453 | 0.552 | 0.630 | 0.284 |  |  |  |  |  | 0.005 | 0.017 | 0.081 | 0.033 | nd | 5.96 | 9.23 | 15.44 | 9.01 | 4.48 | 1.36 | 1.08 | 1.64 | 1.78 | 1.06 |
| FSV-BO | 0.381 | 0.549 | 0.668 | 0.925 | 0.371 |  |  |  |  |  |  |  |  |  |  | 6.60 | 10.20 | 18.10 | 10.70 | 5.70 | 1.60 | 1.30 | 2.00 | 2.10 | 1.30 |
| FSV-BP | 0.351 | 0.497 | 0.654 | 0.752 | 0.314 |  |  |  |  |  |  |  |  |  |  | 6.52 | 9.71 | 17.53 | 8.70 | 5.24 |  |  |  |  |  |
| FSV-BQ | 0.440 | 0.660 | 0.840 | 0.960 | 0.430 |  |  |  |  |  |  |  |  |  |  | 8.40 | 12.20 | 22.20 | 13.50 | 7.70 |  |  |  |  |  |
| FSV-BR | 0.360 | 0.530 | 0.720 | 0.720 | 0.340 |  |  |  |  |  |  |  |  |  |  | 6.70 | 11.00 | 19.40 | 10.75 | 4.05 |  |  |  |  |  |
| FSV-BS | $\geq 0.655$ | $\geq 0.554$ | $\geq 0.455$ | $\geq 0.421$ | $\geq 1.075$ | 0.655 | 0.554 | 0.455 | 0.421 | 1.075 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| FSV-BT | $\geq 0.330$ | $\geq 0.428$ | $\geq 0.549$ | $\geq 0.704$ | $\geq 0.375$ | 0.330 | 0.428 | 0.549 | 0.704 | 0.375 |  |  |  |  |  | 6.48 | 10.02 | 17.76 | 10.10 | 5.38 | 1.70 | 1.37 | 2.30 | 2.23 | 1.23 |
| FSV-BU | 0.377 | 0.547 | 0.677 | 0.706 | 0.291 |  |  |  |  |  |  |  |  |  |  | 6.40 | 9.54 | 18.56 | 8.99 | 4.46 | 1.67 | 1.17 | 2.00 | 2.26 | 1.26 |
| FSV-BV | 0.400 | 0.559 | 0.627 | 0.719 | 0.330 |  |  |  |  |  |  |  |  |  |  | 7.730 | 10.990 | 16.820 | 10.760 | 5.870 | 1.89 | 1.39 | 1.95 | 2.37 | 1.39 |
| FSV-BW | 0.350 | 0.495 | 0.655 | 0.732 | 0.327 |  |  |  |  |  | 0.008 | 0.026 | 0.101 | 0.053 | 0.005 | 6.14 | 9.59 | 18.00 | 10.06 | 4.91 | 1.69 | 1.27 | 2.08 | 2.31 | 1.25 |
| FSV-CC | 0.393 | 0.520 | 0.688 | 0.758 | 0.303 | 0.352 | 0.487 | 0.638 | 0.693 | 0.243 |  |  |  |  |  | 7.73 | 11.54 | 20.42 | 11.73 | $n q$ |  |  |  |  |  |
| FSV-CD | 0.320 | 0.450 | 0.580 | 0.670 | 0.300 |  |  |  |  |  | 0.011 | <0.01 | 0.057 | 0.051 | <0.01 | 7.54 | 11.48 | 20.58 | 11.57 | 6.74 | 1.61 | 1.20 | 1.97 | 2.11 | 1.30 |
| FSV-CE | 0.353 | 0.451 | 0.554 | 0.601 | 0.310 |  |  |  |  |  |  |  |  |  |  | 8.52 | 12.96 | 23.96 | 12.94 | 7.12 |  |  |  |  |  |
| FSV-CF | 0.361 | 0.506 | 0.664 | 0.645 | 0.332 |  |  |  |  |  |  |  |  |  |  | 7.60 | 11.20 | 19.50 | 10.40 | 6.80 |  |  |  |  |  |
| FSV-CG | 0.308 | 0.459 | 0.497 | 0.688 | 0.337 |  |  |  |  |  |  |  |  |  |  | 5.47 | 8.76 | 13.35 | 8.88 | 4.47 | 1.50 | 1.24 | 1.83 | 2.13 | 1.29 |
| FSV-Cl | 0.344 | 0.507 | 0.643 | 0.715 | 0.340 |  |  |  |  |  | 0.008 | nd | 0.091 | 0.043 | 0.013 | 6.84 | 10.87 | 19.42 | 10.74 | 5.52 | 1.72 | 1.34 | 2.18 | 2.26 | 1.31 |
| FSV-CW | 0.493 | 0.624 | 0.784 | 0.993 | 0.700 |  |  |  |  |  | 0.008 | 0.019 | 0.061 | 0.046 | 0.029 | 8.15 | 12.01 | 21.03 | 12.09 | 6.11 | 2.01 | 1.55 | 2.50 | 2.62 | 1.50 |
| FSV-CZ | 0.311 | 0.436 | 0.554 | 0.605 | 0.296 |  |  |  |  |  |  |  |  |  |  | 6.50 | 9.89 | 18.03 | 10.42 | 4.98 | 1.75 | 1.30 | 2.13 | 2.22 | 1.29 |
| FSV-DD | 0.330 | 0.480 | 0.650 | 0.690 | 0.310 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| FSV-DV | $\geq 0.330$ | $\geq 0.471$ | $\geq 0.603$ | $\geq 0.675$ | $\geq 0.256$ | 0.330 | 0.471 | 0.603 | 0.675 | 0.256 |  |  |  |  |  | 6.10 | 9.20 | 15.60 | 8.90 | 3.00 |  |  |  |  |  |
| FSV-EE | 0.339 | 0.479 | 0.601 | 0.678 | 0.312 |  |  |  |  |  |  |  |  |  |  | 6.90 | 10.40 | 19.60 | 12.90 | 7.00 |  |  |  |  |  |
| N | 33 | 33 | 33 | 33 | 33 | 5 | 5 | 5 | 5 | 5 | 11 | 9 | 12 | 11 | 9 | 34 | 34 | 34 | 34 | 33 | 21 | 21 | 21 | 21 | 21 |
| Min | 0.293 | 0.428 | 0.497 | 0.600 | 0.275 | 0.274 | 0.380 | 0.455 | 0.421 | 0.243 | 0.002 | 0.014 | 0.057 | 0.032 | 0.000 | 5.47 | 8.76 | 13.35 | 8.70 | 2.41 | 1.13 | 0.98 | 0.24 | 1.59 | 0.82 |
| Median | 0.351 | 0.497 | 0.654 | 0.719 | 0.327 | 0.330 | 0.471 | 0.549 | 0.675 | 0.289 | 0.008 | 0.021 | 0.090 | 0.043 | 0.007 | 6.75 | 10.30 | 18.48 | 10.44 | 5.67 | 1.72 | 1.34 | 2.08 | 2.26 | 1.30 |
| Max | 0.493 | 0.660 | 0.840 | 0.993 | 0.700 | 0.655 | 0.554 | 0.638 | 0.704 | 1.075 | 0.019 | 0.063 | 0.219 | 0.053 | 0.029 | 8.52 | 12.96 | 23.96 | 13.50 | 7.70 | 2.29 | 1.75 | 2.70 | 2.91 | 1.67 |
| SD | 0.033 | 0.049 | 0.052 | 0.061 | 0.044 | 0.032 | 0.064 | 0.102 | 0.043 | 0.069 | 0.005 | 0.005 | 0.020 | 0.004 | 0.009 | 0.52 | 0.86 | 1.39 | 0.85 | 1.04 | 0.180 | 0.158 | 0.375 | 0.225 | 0.188 |
| CV | 9 | 10 | 8 | 8 | 14 | 10 | 14 | 19 | 6 | 24 | 58 | 26 | 23 | 10 | 125 | 8 | 8 | 8 | 8 | 18 | 10 | 12 | 18 | 10 | 14 |
| Npast | 0 | 0 | 0 | 28 | 30 | 0 | 0 | 0 | 5 | 9 | 0 | 0 | 0 | 9 | 7 | 0 | 0 | 0 | 31 | 32 | 0 | 0 | 0 | 18 | 22 |
| Medianpast |  |  |  | 0.760 | 0.344 |  |  |  | 0.708 | 0.332 |  |  |  | 0.045 | 0.010 |  |  |  | 10.552 | 5.759 |  |  |  | 2.455 | 1.437 |
| SDpast |  |  |  | 0.066 | 0.025 |  |  |  | 0.130 | 0.043 |  |  |  | 0.012 | 0.006 |  |  |  | 0.812 | 0.764 |  |  |  | 0.285 | 0.144 |
| NIST | 0.346 | 0.490 | 0.672 | 0.702 | 0.313 |  |  |  |  |  |  |  |  |  |  | 7.01 | 10.25 | 19.56 | 10.98 | 5.94 | 2.01 | 1.50 | 2.33 | 2.35 | 1.40 |
| NAV | 0.349 | 0.495 | 0.662 | 0.710 | 0.321 | 0.330 | 0.471 | 0.549 | 0.675 | 0.289 | 0.008 | 0.021 | 0.090 | 0.043 | 0.007 | 6.904 | 10.326 | 19.057 | 10.716 | 5.811 | 1.865 | 1.419 | 2.204 | 2.307 | 1.351 |
| NAU | 0.034 | 0.045 | 0.056 | 0.067 | 0.046 | 0.032 | 0.064 | 0.102 | 0.053 | 0.069 | 0.010 | 0.011 | 0.024 | 0.015 | 0.010 | 0.608 | 0.815 | 1.612 | 0.895 | 1.115 | 0.275 | 0.197 | 0.414 | 0.239 | 0.202 |

Round Robin LXVI Laboratory Results

Round Robin LXVI Laboratory Results

Round Robin LXVI Laboratory Results


## Round Robin LXVI Laboratory Results

| Term | Legend |
| :---: | :---: |
| N | Number of (non-NIST) quantitative values reported for this analyte |
| Min | Minimum (non-NIST) quantitative value reported |
| Median | Median (non-NIST) quantitative value reported |
| Max | Maximum (non-NIST) quantitative value reported |
| SD | Standard deviation for (non-NIST) results: $0.741^{*}(3 r d$ Quartile - 1st Quartile) |
| CV | Coefficient of Variation for (non-NIST) results: 100*SD/Median |
| $\mathrm{N}_{\text {past }}$ | Mean of $\mathrm{N}(\mathrm{s})$ from past RR (s) |
| Median ${ }_{\text {past }}$ | Mean of Median(s) from past RR(s) |
| SD ${ }_{\text {past }}$ | Pooled SD from past RR(s) |
| Mean $_{\text {NIST }}$ | Mean of NIST results |
| Srep | NIST's within-vial pooled standard deviation |
| Shet | NIST's among-vial pooled standard deviation |
| Snist | Combined standard deviation for NIST analyses: $\sqrt{ }\left(\mathrm{Srep}^{2}+\mathrm{Shet}^{2}\right)$ |
| NAV | NIST Assigned Value |
|  | $=\left(\right.$ Median + Mean $_{\text {NIST }} / 2$ for analytes reported by NIST analyst(s) |
|  | $=$ Median for analytes reported by $\geq 5$ labs but not NIST |
| NAU | NIST Assigned Uncertainty: $\sqrt{ }\left(S^{2}+S_{b t w}{ }^{2}\right)$ <br> S is the maximum of ( $0.05^{*} \mathrm{NAV}, \mathrm{SD}, \mathrm{S}_{\text {nist }}, \mathrm{eSD}$ ) and Sbtw is the standard deviation between Median and Mean $_{\text {NIST }}$. The expected long-term SD, eSD, is defined in: Duewer et al., Anal Chem 1997;69(7):1406-1413. |
| nd | Not detected (i.e., no detectable peak for analyte) |
| nq | Detected but not quantitatively determined |
| $\geq \mathrm{x}$ | Concentration greater than or equal to $x$ |
| italics | Not explicitly reported but calculated by NIST from reported values |

## Round Robin LXVI Laboratory Results

## Comparability Summary

| Lab | TR | aT | $\mathrm{g} / \mathrm{bT}$ | bC |  | aC | TLy | TbX | TLu |  | L\&Z |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 110.2??? | 2 | 1 | 3 | 1 |  | 2 | 1 | 2 |  |  | 1 |
| 110.3??? | 2 | 1 | 3 | 1 |  | 2 | 1 | 1 |  |  | 1 |
| 119.1??? | 3 | 1 | 3 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
| FSV-BA | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 |  |  | 1 |
| FSV-BB | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FSV-BC | 1 |  |  |  |  |  |  |  |  |  |  |
| FSV-BD | 2 | 2 |  |  |  |  |  |  |  |  |  |
| FSV-BE | 1 | 2 | 1 | 1 |  |  |  |  |  |  |  |
| FSV-BF | 2 | 1 |  | 1 |  |  |  |  |  |  |  |
| FSV-BG | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 |  |  | 1 |
| FSV-BH | 1 | 1 | 3 | 1 | 1 |  | 1 | 2 | 1 | 1 | 1 |
| FSV-BJ | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  |  |
| FSV-BK | 2 | 1 |  |  |  |  |  |  |  |  |  |
| FSV-BL | 2 | 1 |  |  |  |  |  |  |  |  |  |
| FSV-BM | 1 | 1 |  |  |  |  |  |  |  |  |  |
| FSV-BN | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FSV-BNa | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FSV-BO | 2 | 1 | 1 | 1 |  | 1 | 1 | 2 | 4 | 2 | 1 |
| FSV-BP | 1 | 2 |  | 1 |  | 1 | 2 | 1 |  |  | 2 |
| FSV-BQ | 4 | 3 |  |  |  |  |  |  |  |  |  |
| FSV-BR | 1 | 1 |  |  |  |  |  |  |  |  |  |
| FSV-BS | 4 |  |  | 3 | 3 | 1 | 1 | 2 |  |  | 3 |
| FSV-BT | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FSV-BU | 1 | 2 | 1 | 2 |  | 2 | 1 | 1 |  |  | 1 |
| FSV-BV | 2 | 2 | 1 | 2 |  | 1 | 2 | 1 |  |  | 1 |
| FSV-BW | 1 | 1 | 1 | 1 |  | 2 | 1 | 1 |  |  | 1 |
| FSV-CC | 1 | 2 |  |  |  |  |  |  |  |  |  |
| FSV-CD | 1 | 2 | 1 | 4 |  | 3 | 3 | 1 |  |  | 3 |
| FSV-CE | 2 | 3 |  | 4 |  |  |  |  |  |  |  |
| FSV-CF | 1 | 1 |  |  |  |  |  |  |  |  |  |
| FSV-CG | 2 | 3 | 1 | 1 | 2 | 1 | 1 | 2 |  |  | 1 |
| FSV-CI | 1 | 1 | 1 | 1 |  | 2 |  |  | 1 | 1 | 1 |
| FSV-CW | 4 | 2 | 2 | 1 |  | 1 |  | 1 | 3 | 3 | 3 |
| FSV-CZ | 2 | 1 | 1 | 1 |  |  |  |  |  |  |  |
| FSV-DD | 1 |  |  |  |  |  |  |  |  |  |  |
| FSV-DV | 1 | 2 |  |  |  |  |  |  |  |  |  |
| FSV-EE | 1 | 2 |  |  |  |  |  |  |  |  |  |
| NIST | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| n | 38 | 35 | 22 | 26 | 10 | 21 | 20 | 21 | 11 | 10 | 21 |
|  | TR | aT | $\mathrm{g} / \mathrm{bT}$ | bC | tbC | aC | TLy | TbX | TLu | TZ | L\&Z |
| \% 1 | 53 | 57 | 64 | 81 | 60 | 71 | 85 | 71 | 73 | 80 | 81 |
| \% 2 | 37 | 34 | 18 | 8 | 30 | 24 | 10 | 29 | 9 | 10 | 5 |
| \% 3 | 3 | 9 | 18 | 4 | 10 | 5 | 5 | 0 | 9 | 10 | 14 |
| \% 4 | 8 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 9 | 0 | 0 |


| Label | Definition |
| ---: | :--- |
| Lab | Participant code |
| TR | Total Retinol |
| aT | $\alpha$-Tocopherol |
| g/bT | $\gamma / \beta$-Tocopherol |
| bC | Total $\beta$-Carotene |
| tbC | trans- $\beta$-Carotene |
| aC | Total $\alpha$-Carotene |
| TLy | Total Lycopene |
| TbX | Total $\beta$-Cryptoxanthin |
| TLu | Total Lutein |
| TZ | Total Zeaxanthin |
| L\&Z | Total Lutein \& Zeaxanthin |
| n | number of participants providing quantitative data |
| \% 1 | Percent of CS = 1 (within 1 SD of medians) |
| $\%$ 2 | Percent of CS = 2 (within 2 SD of medians) |
| $\% 3$ | Percent of CS = 3 (within 3 SD of medians) |
| $\% 4$ | Percent of CS = 4 (3 or more SD from medians) |

The Comparability Score (CS) of summarizes your measurement performance for a given measurand, relative to the consensus medians. CS is the average distance, in standard deviation units, that your measurement performance characteristics are from the consensus performance. CS is calculated when the number of quantitative values you reported for a measurand, $N_{\text {you }}$, is at least two and the measurand has been reported by 10 or more participants.

```
\(\mathrm{CS}=\operatorname{MIN}\left(4, \operatorname{INT}\left(1+\sqrt{\mathrm{C}^{2}+\mathrm{AP}^{2}}\right)\right)\)
```

$C=$ Concordance $=\sum_{i}^{N_{\text {vou }}} \frac{\text { You }_{i}-\text { Median }_{i}}{N A U_{i}} / N_{\text {you }}$

AP $=$ Apparent Precision $=\sqrt{\sum_{i}\left(\frac{\text { You }_{i}-\text { Median }_{i}}{N A U_{i}}\right)^{2} /\left(N_{\text {you }}-1\right) ~}$
NAU $=$ NIST Assigned Uncertainty, our estimate of the overall measurement standard deviation for each sample. The estimate includes serum heterogeneity, analytical repeatability, and among-participant reproducibility variance components.

For further details, please see: Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT. Micronutrients Measurement Quality Assurance Program: Helping participants use interlaboratory comparison exercise results to improve their longterm measurement performance. Anal Chem 1999;71(9):1870-8.

## Appendix D. Representative "Individualized Report" for RR66

Each participant in RR66 received an "Individualized Report" reflecting their reported results. Each report included a detailed analysis for analytes that were assayed by at least five participants. The following analytes met this criterion in RR66:

- Total Retinol
- trans-Retinol
- Retinyl Palmitate
- $\alpha$-Tocopherol
- $\gamma / \beta$-Tocopherol
- Total $\beta$-Carotene
- trans- $\beta$-Carotene
- Total cis- $\beta$-Carotene
- Total $\alpha$-Carotene
- Total Lycopene
- trans-Lycopene
- Total $\beta$-Cryptoxanthin
- Total Lutein
- Total Zeaxanthin
- Total Lutein \& Zeaxanthin
- Coenzyme Q10

The following fourteen pages are the "Individualized Report" for the analytes evaluated by participant FSV-BA.
Individualized Round Robin LXVI Report: FSV-BA


## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

History

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

History
Her

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum \#357 New \#358 New
\#359 New
\#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum

History

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
$\begin{array}{ll}\Delta \text { You, } \geq x, \text { this RR } & \diamond \text { NIST, this RR } \\ \Delta \text { You, } \geq x, \text { past RRs } & + \text { Others, this RR }\end{array}$

- You, this RR

O You, past RRs
Expectation

History
-

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
$\begin{array}{ll}\Delta \text { You, } \geq x, \text { this RR } & \diamond \text { NIST, this RR } \\ \Delta \text { You, } \geq x, \text { past RRs } & + \text { Others, this RR }\end{array}$

- You, past RRs

History

## Her

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA



Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
History
$\begin{array}{ll}\Delta \text { You, } \geq x, \text { this RR } & \diamond \text { NIST, this RR } \\ \Delta \text { You, } \geq x, \text { past RRs } & + \text { Others, this RR }\end{array}$

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA

Total $\beta$-Cryptoxanthin, $\mu \mathrm{g} / \mathrm{mL}$


For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum \#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

History
$\triangle$ You, $\geq x$, this RR
$\Delta$ You, $\geq x$, past RRs
O You, past RRs
Expectation

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor

## Individualized RR LXVI Report: FSV-BA

Total Lutein\&Zeaxanthin, $\mu \mathrm{g} / \mathrm{mL}$


For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum
\#357 New \#358 New \#359 New \#360 65:\#356
\#351 63:\#341, 63:\#344, 64:\#351

History
$\triangle$ You, $\geq x$, this RR
$\Delta \mathrm{You}, \geq x$, past RRs
You, past RRs

## Comments

Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor
Fresh-frozen, native, multi-donor


## Appendix E. Shipping Package Inserts for RR31

The following five items were included in each package shipped to an RR31 participant:

- Cover letter
- Protocol for Preparation and Analysis of the Ascorbic Acid Solid Control Material
- Preparation and Validation of Ascorbic Acid Solid Control Material Datasheet
- Analysis of Control Materials and Test Samples Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter, preparation protocol, and the two datasheets were enclosed in a sealed waterproof bag along with the samples themselves. The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.

UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg. Maryland 20899-

June 1, 2009

## Dear Colleague:

The samples within this package constitute Vitamin C Round Robin 31 (RR31) of the 2009 Micronutrients Measurement Quality Assurance Program. RR31 consists of four vials of frozen serum test samples (\#37, \#47, \#74; and \#114), one vial of frozen control serum (CS \#2), and one vial of ascorbic acid solid control material (Control). Please follow the attached protocols when you prepare and analyze these samples. If you cannot prepare the solid control solutions gravimetrically, please prepare equivalent solutions volumetrically and report the exact volumes used. (Routine 0.5 g gravimetric measurements are generally 10 -fold more accurate than routine 0.5 mL volumetric measurements.)

Please use the control serum to validate the performance of your measurement system before you analyze the test samples. The target value and $\approx 95 \%$ confidence interval for target value and $\approx 95 \%$ confidence interval for CS \#2 is $28.1 \pm 1.0 \mu \mathrm{~mol} / \mathrm{L}$ of sample.

The report for RR30 was e-mailed May 15, 2009. If you find your results for RR30 unsatisfactory, we recommend that you obtain Standard Reference Material (SRM) 970 Ascorbic Acid in Serum to validate your methodology and value assign in-house control materials. This SRM may be purchased from the Standard Materials Reference Program at NIST (Tel: 301-975-6776, Fax: 301-948-3730, or e-mail: srminfo@nist.gov).

Please be aware that sample contact with any oxidant-contaminated surface (vials, glassware, etc.) may degrade your measurement system's performance (SA Margolis and E Park, "Stability of Ascorbic Acid in Solutions in Autosampler Vials", Clinical Chemistry 2001, 47(8), 1463-1464). You should suspect such degradation if you observe unusually large variation in replicate analyses.

If you have any questions or concerns about the Vitamin C Micronutrients Measurement Quality Assurance Program please contact Jeanice Brown Thomas at phone: 301-975-3120, fax: 301-977-0685, or e-mail: jbthomas@nist.gov.

We ask that you return your results for these RR31 samples by September 28, 2009. We would appreciate receiving your results as soon as they become available. Please use the attached form. Your results will be kept confidential.

$\begin{array}{ll}\text { Enclosures: } & \text { Protocols, Preparation and Analysis of Control Materials and Analysis of Test Samples } \\ & \text { RR31 Report Form for Ascorbic Acid Solid Control Material Preparation } \\ \text { RR31 Report Form for Control Material and Test Sample Analyses }\end{array}$

# Micronutrient Measurement Quality Assurance Program for Vitamin C 

Please Read Through Completely BEFORE Analyzing Samples

## Protocol for Preparation and Analysis of the Ascorbic Acid Solid Control Material

The ascorbic acid solid control material (in the amber vial) should be prepared and used in the following manner:

1) Prepare at least 500 mL of $5 \%$ mass fraction metaphosphoric acid (MPA) in distilled water. This solution will be referred to as the "Diluent" below.
2) Weigh 0.20 to 0.22 g of the ascorbic acid solid control material to 0.0001 g (if possible), dissolve it in the Diluent in a 100 mL volumetric flask, and dilute with the Diluent to the 100 mL mark. Weigh the amount of Diluent added to 0.1 g . Record the weights. The resulting material will be referred to as the "Stock Solution" below.
3) Prepare three dilute solutions of the Stock Solution as follows:

Dilute Solution 1: Weigh 0.500 mL of the Stock Solution to 0.0001 g into a 100 mL volumetric flask; dilute with Diluent to the 100 mL mark. Record the weight.

Dilute Solution 2: Weigh 0.250 mL of the Stock Solution to 0.0001 g into a 100 mL volumetric flask; dilute with Diluent to the 100 mL mark. Record the weight.

Dilute Solution 3: Weigh 0.125 mL of the Stock Solution to 0.0001 g into a 100 mL volumetric flask; dilute with Diluent to the 100 mL mark. Record the weight.
4) Calculate and record the total ascorbic acid concentrations, [TAA], in these Dilute Solutions. If you follow the above gravimetric preparation directions, the [TAA] in $\mu \mathrm{mol} / \mathrm{L}$ is calculated:

$$
[\mathrm{TAA}]_{\mathrm{DS}}=\frac{(\mathrm{g} \text { Stock Solution in Dilute Solution }) \cdot(\mathrm{g} \mathrm{AA} \text { in Stock Solution }) \cdot(56785 \mu \mathrm{~mol} / \mathrm{g} \cdot \mathrm{~L})}{(\mathrm{g} \text { AA in Stock Solution })+(\mathrm{g} \text { Diluent in Stock Solution })}
$$

For example, if you prepared the Stock Solution with 0.2000 g of solid ascorbic acid and 103.0 g of Diluent, then 0.5 mL of the Stock Solution should weigh $(0.2+103) / 200=0.52 \mathrm{~g}$ and $[\text { TAA }]_{\text {DS } 1}=(0.52 \mathrm{~g})(0.2 \mathrm{~g}) \cdot(56785 \mu \mathrm{~mol} / \mathrm{g} \cdot \mathrm{L}) /(0.2+103 \mathrm{~g})=57.2 \mu \mathrm{~mol} / \mathrm{L}$. Likewise, 0.25 mL of the Stock Solution should weigh 0.26 g and $[\mathrm{TAA}]_{\mathrm{DS} 2}=29.4 \mu \mathrm{~mol} / \mathrm{L}$ and 0.125 mL should weigh 0.13 g and $[\mathrm{TAA}]_{\mathrm{DS} 3}=14.2 \mu \mathrm{~mol} / \mathrm{L}$.
5) Measure the ultraviolet absorbance spectrum of Dilute Solution 1 against the Diluent as the blank using paired 1 cm path length cuvettes. Record the absorbance at 242, 243, 244, and 245 nm . Record the maximum absorbance ( $\mathrm{A}_{\max }$ ) within this region. Record the wavelength ( $\lambda_{\max }$ ) at which this maximum occurs.

The extinction coefficient $\left(\mathrm{E}^{1 \%}\right)$ of ascorbic acid at $\lambda_{\text {max }}$ (using a cell with a 1 cm path length) of Dilute Solution \#1 can be calculated:

$$
\mathrm{E}^{1 \% \%}\left(\frac{\mathrm{dL}}{\mathrm{~g} \cdot \mathrm{~cm}}\right)=\frac{\left(\mathrm{A}_{\text {max }}\right) \cdot((\mathrm{g} \mathrm{AA} \text { in Stock Solution })+(\mathrm{g} \text { Diluent in Stock Solution }))}{(\mathrm{g} \text { Stock Solution in Dilute Solution } 1) \cdot(\mathrm{g} \mathrm{AA} \text { in Stock Solution })}
$$

If your spectrophotometer is properly calibrated, $\lambda_{\max }$ should be between 243 and 244 nm and $\mathrm{E}^{1 \%}$ should be $550 \pm 30 \mathrm{dL} / \mathrm{g} \cdot \mathrm{cm}$. If they are not, you should recalibrate the wavelength and/or absorbance axes of your spectrophotometer and repeat the measurements.
6) Measure and record the concentration of total ascorbic acid in all three dilute solutions and in the 5\% MPA Diluent in duplicate using exactly the same method that you will use for the serum control materials and test samples, including any enzymatic treatment. We recommend that you analyze these solutions in the following order: Diluent, Dilute Solution 1, Dilute Solution 2, Dilute Solution 3, Dilute Solution 3, Dilute Solution 2, Dilute Solution 1, Diluent.
a) Compare the values of the duplicate measurements. Are you satisfied that your measurement precision is adequate?
b) Compare the measured with the calculated [TAA] values. This is most conveniently done by plotting the measured values on the $y$-axis of a scatterplot against the calculated values on the x-axis. The line through the four \{calculated, measured\} data pairs should go through the origin with a slope of 1.0. Are you satisfied with the agreement between the measured and calculated values?

Do not analyze the serum control materials or test samples until you are satisfied that your system is performing properly!
7) Once you have confirmed that your system is properly calibrated, analyze the serum control CS \#1 (see protocol below). The target values for this materials is $8.4 \pm 0.7 \mu \mathrm{~mol} / \mathrm{L}$ of sample. If your measured values are not close to this value, please review your sample preparation procedure and whether you followed exactly the same measurement protocol the solutions prepared from the solid control material as you used for these serum controls. If the protocols differ, please repeat from Step 6 using the proper protocol. If the proper protocol was used, your measurement system may not be suitable for MPA-preserved samples; please contact us at 301-975-3120 or jbthomas@NIST.gov.
Do not analyze the test samples until you are satisfied that your system is performing properly and is suitable for the analysis of MPA-preserved serum!

## Protocol for Analysis of the Serum Control Materials and Test Samples

The serum control material and test samples are in sealed ampoules. They were prepared by adding equal volumes of $10 \%$ MPA to spiked human serum. We have checked the samples for stability and homogeneity. Only the total ascorbic acid is stable. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, only total ascorbic acid should be reported. The serum control material and test samples should be defrosted by warming at $20^{\circ} \mathrm{C}$ for not more than 10 min otherwise some irreversible degradation may occur.

Each serum test sample contains between 0.0 and $80.0 \mu \mathrm{~mol}$ of total ascorbic acid/L of solution. The total ascorbic acid in each ampoule should be measured in duplicate. Please report your results in $\mu \mathrm{mol} /(\mathrm{L}$ of the sample solution) rather than $\mu \mathrm{mol} /(\mathrm{L}$ of serum NIST used to prepare the sample).
$\qquad$
$\qquad$
Vitamin C Round Robin 31NIST Micronutrient Measurement Quality Assurance Program
Preparation and Validation of Ascorbic Acid Solid Control Material
STOCK SOLUTION
Mass of ascorbic acid in the Stock Solution ..... g
Mass of 5\% MPA Diluent added to the 100 mL volumetric flask ..... g
DILUTE SOLUTION 1
Mass of added stock solution ( 0.5 mL ) ..... g
Mass of 5\% MPA Diluent added to the 100 mL volumetric flask ..... g
Absorbance of Dilute Solution 1 at 242 nm

$\qquad$ ..... AU
Absorbance of Dilute Solution 1 at 243 nm

$\qquad$ ..... AU
Absorbance of Dilute Solution 1 at 244 nm ..... AU
Absorbance of Dilute Solution 1 at 245 nm ..... AU
Absorbance of Dilute Solution absorbance maximum ..... AU
Wavelength of maximum absorbance ..... nm
Calculated $\mathrm{E}^{1 \%}$ ..... $\mathrm{dL} / \mathrm{g} \cdot \mathrm{cm}$
Calculated [TAA] ${ }_{\text {DS } 1}$ ..... $\mu \mathrm{mol} / \mathrm{L}$
DILUTE SOLUTION 2
Mass of added stock solution ( 0.25 mL ) ..... g
Mass of 5\% MPA Diluent added to the 100 mL volumetric flask ..... g
Calculated $[\mathrm{TAA}]_{\mathrm{DS} 2}$ ..... $\mu \mathrm{mol} / \mathrm{L}$
DILUTE SOLUTION 3
Mass of added stock solution ( 0.125 mL ) ..... g
Mass of 5\% MPA Diluent added to the 100 mL volumetric flask ..... g
Calculated $[\mathrm{TAA}]_{\text {DS3 }}$ ..... $\mu \mathrm{mol} / \mathrm{L}$

Participant \#: $\qquad$ Date: $\qquad$

# Vitamin C Round Robin 31 NIST Micronutrient Measurement Quality Assurance Program Analysis of Control Materials and Test Samples 

| Sample | Replicate 1 | Replicate 2 | Units |
| :---: | :---: | :---: | :---: |
| Dilute Solution 1 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Dilute Solution |
| Dilute Solution 2 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Dilute Solution |
| Dilute Solution 3 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Dilute Solution |
| 5\% MPA Diluent |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Diluent |
| CS \#2 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Sample <br> Target: $28.1 \pm 1.0 \mu \mathrm{~mol} / \mathrm{L}$ |
| Serum Test Sample \#37 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Sample |
| Serum Test Sample \#47 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Sample |
| Serum Test Sample \#74 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Sample |
| Serum Test Sample \#114 |  |  | $\mu \mathrm{mol} / \mathrm{L}$ of Sample |

Were samples frozen upon receipt? Yes | No
Analysis method: HPLC-EC | HPLC-Fluor DAB | HPLC-OPD | HPLC-UV | AO-OPD | Other If "Other", please describe:

## COMMENTS:

MMQAP
100 Bureau Drive, Stop 8392
Gaithersburg, MD 20899-8392

Fax: 301-977-0685
Email: david.duewer@nist.gov
$\qquad$

## Vitamin C Round Robin 31

NIST Micronutrients Measurement Quality Assurance Program

## Packing List and Shipment Receipt Confirmation Form

This box contains one vial each of the following six VitC M ${ }^{2}$ QAP samples:

| Label | Form |  |
| :---: | :---: | :---: |
| VitC \#37 |  | Liquid frozen (1:1 serum:10\% MPA) |
| VitC \#47 |  | Liquid frozen (1:1 serum:10\% MPA) |
| VitC \#74 |  | Liquid frozen (1:1 serum:10\% MPA) |
| VitC \#114 |  | Liquid frozen (1:1 serum:10\% MPA) |
| CS \#2 | Liquid frozen (1:1 serum:10\% MPA) |  |
| Control | Solid AA |  |

Please 1) Open the pack immediately
2) Check that it contains one vial each of the above samples
3) Check if the samples arrived frozen
4) Store the samples at $-20^{\circ} \mathrm{C}$ or below until analysis
5) Complete the following information
6) Fax the completed form to us at 301-977-0685
(or email requested information to david.duewer@nist.gov)

1) Date this shipment arrived: $\qquad$
2) Are all of the vials intact? Yes | No If "No", which one(s) were damaged?
3) Was there any dry-ice left in cooler? Yes | No
4) Did the samples arrive frozen? Yes | No
5) At what temperature are you storing the samples? $\qquad$ ${ }^{\circ} \mathrm{C}$
6) When do you anticipate analyzing these samples? $\qquad$

## Your prompt return of this information is appreciated.

The M ${ }^{2}$ QAP Gang

## Appendix F. Final Report for RR31

The following three pages are the final report as provided to all participants:

- Cover letter.
- An information sheet that:
o describes the contents of the "All-Lab" report,
o describes the content of the "Individualized" report,
o describes the nature of the test samples and details their previous distributions, if any, and
o summarizes aspects of the study that we believe may be of interest to the participants.

October 30, 2009
Dear Colleague:
Enclosed is the summary report of the results for Round Robin 31 (RR31) for the measurement of total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid) in human serum. Included in this report are a summary of data for all laboratories and an individualized summary of your laboratory's measurement performance. The robust median is used to estimate the consensus value for all samples, the "median absolute deviation from the median" (MADe) is used to estimate the expected standard deviation, and the coefficient of variation (CV) is defined as $100 \times \mathrm{MADe} /$ median.

RR31 consisted of four test samples (\#37, \#47, \#74, and \#114), one serum control material (CS\#2), and one solid control material for preparation of TAA control solutions. Details regarding the samples can be found in the enclosed report.

If you have concerns regarding your laboratory's performance, we suggest that you obtain and analyze a unit of Standard Reference Material (SRM) 970, Vitamin C in Frozen Human Serum. SRM 970 can be purchased from the NIST SRM Program at phone: 301-975-6776; fax: 301-948-3730. If your measured values do not agree with the certified values, we suggest that you contact us for consultation.

Samples for the first vitamin C round robin (RR32) of the 2010 NIST_Micronutrients Measurement Quality Assurance Program will be shipped during the week of December 7, 2009.

If you have questions or concerns regarding this report, please contact David Duewer at 301-975-3935; e-mail: david.duewer@nist.gov or me at 301-975-3120; e-mail: jbthomas@nist.gov; or fax: 301-977-0685.



David L. Duewer, Ph.D
Research Chemometrician
Analytical Chemistry Division
Chemical Science and Technology Laboratory

## Enclosures

Cc: L. C. Sander

The NIST M ${ }^{2}$ QAP Vitamin C Round Robin 31 (RR31) report consists of

| Page | "Individualized" Report |
| :---: | :--- |
| 1 | Summarizes your reported values for the nominal $55 \mathrm{mmol} / \mathrm{L}$ solution you prepared from the <br> ascorbic acid solid control sample, the serum control sample, and the four serum test <br> samples. |
| 2 | Graphical summary of your RR31 sample measurements. |


| Page | "All Lab" Report |
| :---: | :--- |
| 1 | A tabulation of results and summary statistics for Total Ascorbic Acid [TAA] in the RR31 <br> samples and control/calibration solutions. |

Serum-based Samples. One serum control and four unknowns were distributed in RR31.
CS\#2 SRM 970 level 2, ampouled in mid-1998.
S31:1 Serum 37, ampouled in late 2001, previously distributed as sample S17:2 (RR17, Fall 02), S18:1 (RR18, Spring 03), S20:1 (RR20, Spring 04), S22:2 (RR22, Spring 05), S23:2 (RR23, Fall 05), S27:1 (RR27, Fall 07).
S31:2 Serum 47, ampouled in late 2001, previously distributed as sample S18:2 (RR18, Spring 03), S19:3 (RR19, Fall 03), S21:3 (RR21, Fall 04), S22:3 (RR22, Spring 05) and S24:2 (RR24, Spring 06)., S26:2 (RR26, Spring 07)
S31:3 SRM 970 level 1, ampouled in mid-1998
S31:4 Serum 114, ampouled in 1995, previously distributed as sample 188a in (RR9, Summer 96) and 27:3 (RR27, Fall 07)

## Results.

1) Most participants who prepared the four $5 \%$ MPA control/calibration solutions (the three "Dilute Solutions" and the "Diluent") did so correctly. The criteria used to evaluate this success are: the density of the $5 \%$ MPA ( $\approx 1.03 \mathrm{gm} / \mathrm{mL}$ ), the observed wavelength maximum of "Dilute Solution $\# 1 "(\approx 244 \mathrm{~nm})$, the observed absorbance at that maximum ( $\approx 0.58 \mathrm{OD}$ ), the calculated $\mathrm{E}^{1 \%} \# 1 "(\approx 560$ $\mathrm{dL} / \mathrm{g} \cdot \mathrm{cm}$ ). On the evidence of MPA density, one participant prepared the solutions in $2.5 \%$ MPA; this may have contributed to systematically low results for the unknowns. On the evidence of the maximum absorbance and calculated $\mathrm{E}^{1 \%}$ \#1, one participant had spectrophotometer issues; this had no impact on the [TAA] measurements.
2) The Measured = a+b*Gravimetric calibration parameters for the control/calibration solutions (columns 10 to 13 of the All Lab Report) indicate that the measurement systems for all participants are linear ( $\mathrm{R}^{2}$ close to 1 and RMS close to 0.0 ) and reasonably well calibrated (intercepts range from -1.0 to 0.9 and slopes range from 0.96 to 1.14 ).
3) The Measured $=\mathrm{p}+\mathrm{q}$ *Median regression parameters for samples S31:1 to S31:4 (columns 23 to 26 of the All Lab Report) confirm the linearity of most measurement systems ( $\mathrm{R}^{2}$ close to 1 and RMS close to 0.0 ).
4) There is no evidence of sample degradation in any of the materials.
5) The Figure below displays the interlaboratory MADe (a robust estimate of the standard deviation) as a function of the interlaboratory median for both the "Unkowns" and the "Controls". The interlab
reproducibility precision, $\mathrm{SD}_{\text {unk }}$, for the unknowns is reasonably well described by the function

$$
\mathrm{SD}_{\mathrm{unk}}=\sqrt{1.3^{2}+(0.080 \times[\mathrm{TAA}])^{2}} .
$$

That is, $\mathrm{SD}_{\mathrm{unk}}$ is 1) at least $1.3 \mu \mathrm{~mol} / \mathrm{L}$ regardless of the [TAA] and 2 ) at high [TAA] levels the relative $\mathrm{SD}_{\text {unk }}, \mathrm{RSD}_{\text {unk }}$, is about $8 \%$. The $\mathrm{SD}_{\text {unk }}$ is displayed as a thick black line, $\mathrm{RSD}_{\text {unk }}$ is displayed as a blue line.


While there are too few data for confident assessment, the reproducibility precision for the two materials that have been provided as Controls, $\mathrm{SD}_{\mathrm{CS}}$, is consistently smaller than for the Unknowns. It appears, therefore, that there is "room for improvement" in the interlaboratory comparability of [TAA] measurements.

## Appendix G. "All-Lab Report" for RR31

The following single page is the "All-Lab Report" as provided to all participants, with two exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.

The data summary in the "All-Lab Report" has been altered to ensure confidentiality of identification codes assigned to laboratories.

| Measured, $\mu \mathrm{mol} / \mathrm{L}$ |  |  |  |  |  |  |  |  |  | Measured $=p+q^{*}$ Median |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: | ---: | ---: | :---: | :---: | :---: | :---: |
| CS\#2 | S31:1 | S31:2 | S31:3 | S31:4 | Inter | Slope | $R^{2}$ | RMS |  |  |  |  |
| 32.0 | 22.1 | 33.8 | 7.7 | 29.4 | -1.09 | 1.05 | 0.999 | 0.5 |  |  |  |  |
| 28.4 | 23.2 | 35.4 | 8.5 | 29.9 | -0.46 | 1.06 | 1.000 | 0.2 |  |  |  |  |
| 27.5 | 16.7 | 28.5 | 7.6 | 23.2 | -0.14 | 0.82 | 0.987 | 1.3 |  |  |  |  |
| 31.8 | 25.7 | 38.8 | 9.7 | 34.9 | -0.17 | 1.18 | 0.995 | 1.1 |  |  |  |  |
| 28.0 | 22.1 | 33.7 | 8.2 | 28.6 | -0.31 | 1.01 | 1.000 | 0.1 |  |  |  |  |
| 28.2 | 21.4 | 32.7 | 8.3 | 28.1 | 0.04 | 0.97 | 1.000 | 0.2 |  |  |  |  |
| 28.4 | 21.5 | 35.3 | 10.5 | 28.7 | 1.55 | 0.97 | 0.988 | 1.4 |  |  |  |  |
| 30.1 | 26.0 | 37.8 | 11.1 | $b$ | 2.23 | 1.06 | 1.000 | 0.4 |  |  |  |  |
| 30.0 | 24.5 | 36.0 | 10.5 | 28.0 | 2.29 | 0.97 | 0.983 | 1.7 |  |  |  |  |
| 28.7 | 22.1 | 32.7 | 11.3 | 27.0 | 4.00 | 0.83 | 0.995 | 0.8 |  |  |  |  |
|  | 21.2 | 32.5 | 8.5 | 31.5 | 0.00 | 1.01 | 0.972 | 2.3 |  |  |  |  |
| 25.9 | 18.2 | 31.3 | 7.4 | 24.7 | -1.17 | 0.93 | 0.989 | 1.3 |  |  |  |  |
| 27.9 | 21.5 | 32.1 | 7.8 | 25.7 | -0.11 | 0.94 | 0.995 | 0.9 |  |  |  |  |


| - |
| :---: |
| N |
| $\underset{\sim}{\sim} \underset{\sim}{\circ} \underset{\sim}{\circ}$ |
| $\underset{\sim}{\sim}$ |
| ت- |


|  |
| :---: |
| - $\sim_{\text {d }}^{\substack{\text {-1 }}}$ |
|  |  |
|  |
|  |
|  |
|  |  |
|  |
|  |




|  |
| :---: |
|  |
|  |
|  |
|  |


| 9, |  |
| :---: | :---: |
| $\left\|\begin{array}{ccc} 0 & 0 & 0 \\ & 0 & 0 \end{array}\right\|$ |  |
|  |  |
|  |  |
|  |  |
| $\left\|\begin{array}{ccc} 0 & \infty \\ \underset{\sim}{\mathrm{~N}} & \underset{\sim}{\mathrm{~N}} \end{array}\right\|$ |  |
| $\left\lvert\, \begin{array}{ccc} 0 & N \\ & \stackrel{n}{\mathrm{~N}} \end{array}\right.$ |  |
|  | $\stackrel{N}{N}$ |

a) $5 \%$ Trichloroacetic acid solution
b) Mislabeled sample

## Appendix H. Representative "Individualized Report" for RR31

Each participant in RR31 received an "Individualized Report" reflecting their reported results. The following two pages are the "Individualized Report" for participant "VC-MA".

## Vitamin C "Round Robin" 31 Report: Participant VC-MA


[TAA] mmol/Lsample

| Date | RR | Sample | $\mathrm{Rep}_{1}$ | $\mathrm{Rep}_{2}$ | $\mathrm{F}_{\text {adj }}$ | Mean | SD ${ }_{\text {dup }}$ | N | Mean | $\mathrm{SD}_{\text {repeat }}$ | $\mathrm{SD}_{\text {reprod }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 10/17/05 | 23 | CS\#2 | 29.4 | 30.5 | 1.0 | 30.0 | 0.8 | 6 | 28.9 | 0.5 | 1.8 |
| 03/09/06 | 24 | CS\#2 | 29.2 | 29.1 | 1.0 | 29.2 | 0.1 |  |  |  |  |
| 08/28/06 | 25 | CS\#2 | 27.2 | 28.1 | 1.0 | 27.6 | 0.6 |  |  |  |  |
| 10/05/07 | 27 | CS\#2 | 28.1 | 27.4 | 1.0 | 27.7 | 0.5 |  |  |  |  |
| 08/11/08 | 29 | CS\#2 | 27.2 | 27.2 | 1.0 | 27.2 | 0.0 |  |  |  |  |
| 09/10/09 | 31 | CS\#2 | 31.8 | 32.2 | 1.0 | 32.0 | 0.3 |  |  |  |  |
| 03/20/03 | 18 | S18:2 | 35.1 | 36.0 | 1.0 | 35.6 | 0.6 | 7 | 34.9 | 0.3 | 1.1 |
| 11/13/03 | 19 | S19:3 | 35.9 | 35.8 | 1.0 | 35.9 | 0.1 |  |  |  |  |
| 09/13/04 | 21 | S21:3 | 33.2 | 32.9 | 1.0 | 33.0 | 0.2 |  |  |  |  |
| 03/08/05 | 22 | S22:3 | 35.7 | 35.6 | 1.0 | 35.6 | 0.1 |  |  |  |  |
| 03/09/06 | 24 | S24:2 | 35.8 | 35.5 | 1.0 | 35.6 | 0.2 |  |  |  |  |
| 03/20/07 | 26 | S26:2 | 35.0 | 35.4 | 1.0 | 35.2 | 0.3 |  |  |  |  |
| 09/10/09 | 31 | S31:2 | 33.9 | 33.7 | 1.0 | 33.8 | 0.2 |  |  |  |  |
| 09/23/98 | 11 | S11:1:A | 15.5 | 13.9 | 0.5 | 7.4 | 0.6 | 12 | 8.2 | 0.3 | 0.5 |
| 04/02/99 | 12 | S12:1:A | 14.5 | 15.8 | 0.5 | 7.6 | 0.5 |  |  |  |  |
| 09/17/01 | 13 | S13:1 | 8.4 | 8.5 | 1.0 | 8.5 | 0.1 |  |  |  |  |
| 09/27/01 | 14 | S14:3 | 8.0 | 7.7 | 1.0 | 7.8 | 0.2 |  |  |  |  |
| 09/18/01 | 15 | S15:1 | 8.9 | 8.7 | 1.0 | 8.8 | 0.1 |  |  |  |  |
| 11/18/02 | 16 | S16:1 | 8.8 | 8.8 | 1.0 | 8.8 | 0.0 |  |  |  |  |
| 11/13/03 | 19 | S19:4 | 7.8 | 8.6 | 1.0 | 8.2 | 0.5 |  |  |  |  |
| 02/23/04 | 20 | S20:3 | 8.3 | 8.1 | 1.0 | 8.2 | 0.1 |  |  |  |  |
| 10/17/05 | 23 | S23:4 | 8.6 | 8.8 | 1.0 | 8.7 | 0.1 |  |  |  |  |
| 08/28/06 | 25 | S25:1 | 8.7 | 8.5 | 1.0 | 8.6 | 0.2 |  |  |  |  |
| 08/11/08 | 29 | S29:2 | 8.3 | 8.4 | 1.0 | 8.3 | 0.1 |  |  |  |  |
| 09/10/09 | 31 | S31:3 | 7.3 | 8.1 | 1.0 | 7.7 | 0.5 |  |  |  |  |
| 06/19/96 | 09 | S09:2 | 51.7 | 51.1 | 0.5 | 25.7 | 0.2 | 3 | 27.9 | 0.4 | 2.0 |
| 10/05/07 | 27 | S27:3 | 28.5 | 28.6 | 1.0 | 28.5 | 0.1 |  |  |  |  |
| 09/10/09 | 31 | S31:4 | 29.0 | 29.9 | 1.0 | 29.4 | 0.7 |  |  |  |  |

Please check our records against your records. Send corrections and/or updates to...

Micronutrients Measurement Quality Assurance Program
National Institute of Standards and Technology
100 Bureau Drive Stop 8392

## Vitamin C "Round Robin" 31 Report: Participant VC-MA

Total Ascorbic Acid, $\mu \mathrm{mol} / \mathrm{mL}$




For details of the construction and interpretation of these plots, see:
Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

## Sample

Comments
S31:1 VitC \#37 previously distributed in RRs 17, 18, 20, 22, 23, 27
S31:2 VitC \#47, previously distributed in RRs 18, 19, 21, 22, 24, 26
S31:3 VitC \#74, previously distributed in RRs 11, 12, 13, 14, 15, 16, 19, 20, 23, 25, 29
S31:4 VitC \#114, previously distributed in RRs 9, 27

